Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Damn I thought this was going up

<< Previous

Bullboard Posts

Next >>

Comment by GameChangerBeton May 13, 2021 12:35pm

119 Views

Post# 33192262

RE:RE:RE:RE:RE:RE:Damn I thought this was going up

YukonJezza wrote:

GameChangerBet wrote: $3.56 is possible, especially given the market volatility currently, but from my observation it appears that most of the folks invested in ATE, including myself, are in it for more than a plus or minus 50 cent gain. If you're a trader than certainly those moves matter, but otherwise, in the bigger scheme of things, it's essentially irrelevant.

I have shares. I would like to average down, not up. We are caught in the summer doldrums. It's only May. There is plenty of time for anything to happen.

Fair enough

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China